Skip Navigation



European Heart Journal Advance Access published online on March 23, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm025
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/7/777    most recent
ehm025v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mulders, A. C.M.
Right arrow Articles by Michel, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulders, A. C.M.
Right arrow Articles by Michel, M. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Sphingomyelin metabolism and endothelial cell function

Arthur C.M. Mulders, Stephan L.M. Peters and Martin C. Michel*

Academic Medical Center, Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands

* Corresponding author. Tel: +31-20-566-6762; fax: +31-20-696-5976. E-mail address: m.c.michel@amc.uva.nl

This editorial refers to ‘Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow’ by W. Doehner et al., doi:10.1093/eurheartj/ehl541

The first 10% of the full text of this article appears below.

Serum activity of the enzyme secretory sphingomyelinase (sSM) is higher in patients with congestive heart failure (CHF) than in those with arterial hypertension or in healthy controls; more importantly, this elevation is not related to the aetiology of CHF, but rather to its severity, and well correlated with peak oxygen uptake, cytokine activation, skeletal muscle strength, and peripheral vasodilator capacity.1 In a proportional hazard analysis, serum sSM activity was related to survival independent of age, NYHA class, or blood pressure. As sSM is largely derived from the endothelium, these findings highlight the emerging role of endogenous sphingolipids as regulators of cardiovascular function and the role of the endothelium in such regulation. Against this background, we will highlight some recent findings on the complex interplay between the local formation of sphingomyelin metabolites and the endothelium.

Sphingomyelin metabolite-mediated signalling

Various stressful stimuli can activate different isoforms of sphingomyelinase, which catalyses . . . [Full Text of this Article]

Barrier function

Nitric oxide release

Vascular inflammation

Embryonic vascular maturation

Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow
Wolfram Doehner, Alexander C. Bunck, Mathias Rauchhaus, Stephan von Haehling, Frank M. Brunkhorst, Mariantonietta Cicoira, Carsten Tschope, Piotr Ponikowski, Ralf A. Claus, and Stefan D. Anker
EHJ 2007 28: 821-828. [Abstract] [FREE Full Text]